Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
TEVA
TEVA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TEVA News
Investment Outlook Comparison: Eli Lilly vs. Teva
1d ago
Fool
Eli Lilly vs. Teva: A Market Comparison
1d ago
NASDAQ.COM
SPDW ETF 52-Week Price Range Analysis
Jun 26 2026
NASDAQ.COM
Teva Submits NDA for Ecopipam to Treat Pediatric Tourette Syndrome
Jun 22 2026
NASDAQ.COM
Teva Pharmaceuticals Transitions to Innovative Drug Development
Jun 19 2026
Fool
Teva Pharmaceuticals Reports Strong Q1 Performance
Jun 19 2026
NASDAQ.COM
Teva Seeks FDA Approval for Ecopipam in Pediatric Tourette Syndrome
Jun 18 2026
seekingalpha
Teva Pharmaceuticals Releases Q2 2026 Aide Memoire
Jun 18 2026
Newsfilter
Teva Submits NDA for Ecopipam to Treat Pediatric Tourette Syndrome
Jun 18 2026
Newsfilter
Teva Pharmaceuticals to Release Q2 2026 Financial Results
Jun 18 2026
Newsfilter
Medincell SA Reports Growth Strategy Success with Strong Financials
Jun 17 2026
Yahoo Finance
Teva Pharmaceutical's Recovery: Challenges and Opportunities in Biosimilars
Jun 12 2026
Fool
Biotech Sector Sees Surge in FDA and Global Approvals
Jun 12 2026
NASDAQ.COM
Teva Completes Acquisition of Emalex Biosciences for $700 Million
Jun 11 2026
NASDAQ.COM
Teva Acquires Emalex Biosciences to Enhance Pipeline for Tourette Syndrome
Jun 10 2026
Newsfilter
Alvotech's AVT16 Biosimilar Application Accepted by FDA
Jun 08 2026
seekingalpha
Show More News
